FANCF Antibody, Biotin conjugated
Description
Introduction to FANCF Antibody, Biotin Conjugated
FANCF (Fanconi Anemia Complementation Group F) antibody conjugated to biotin is a specialized immunological reagent designed for detecting the FANCF protein, a critical component of the Fanconi anemia DNA repair pathway. Biotin conjugation enables high-sensitivity detection through streptavidin-based amplification systems, making it ideal for applications like ELISA and Western blotting .
Target and Reactivity
Primary Uses
-
ELISA: Optimal for quantitative detection of FANCF in human samples .
-
Western Blot (WB): Validated for identifying FANCF in lysates .
-
Signal Amplification: Biotin-streptavidin systems enhance sensitivity for low-abundance targets .
Advantages of Biotin Conjugation
-
Versatility: Compatible with enzymatic (HRP) or fluorescent streptavidin conjugates .
-
Multiplexing: Enables simultaneous detection of multiple targets in complex assays .
Biotinylation Protocol
Biotin is typically attached via amine-reactive NHS esters, targeting lysine residues on the antibody. Long-armed biotin (e.g., biotin-XX) minimizes steric hindrance, improving avidin binding efficiency .
Critical Quality Metrics
-
Specificity: Polyclonal design ensures broad epitope recognition within AA 295–341 .
-
Cross-Reactivity: Validated for human reactivity; no cross-species reactivity reported .
-
Preservative Safety: Contains ProClin-300, a hazardous preservative requiring trained handling .
Comparative Analysis of Conjugation Techniques
Research highlights key differences between biotinylation methods:
Research Findings and Validation
-
Clinical Relevance: FANCF mutations are linked to Fanconi anemia, a disorder causing bone marrow failure and cancer predisposition. This antibody aids in studying DNA repair mechanisms .
-
Performance in IHC: ZBPA-conjugated biotinylated antibodies show superior specificity in tissue microarrays compared to conventional kits (e.g., Lightning-Link) .
Limitations and Handling Precautions
-
Sensitivity: Requires optimization of antibody dilution for low-expression targets .
-
Hazardous Components: ProClin-300 necessitates careful disposal and handling .
Future Directions
Emerging techniques like tyramide signal amplification (e.g., Biotin XX Tyramide SuperBoost Kit) may further enhance detection limits for FANCF in complex samples .
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Loss of heterozygosity (LOH) in Fanconi anemia (FA) genes appears to be a frequent occurrence in the development of head and neck squamous cell carcinomas. Here, LOH was observed in 57% of patients, and other mutation types may increase this mutation frequency. Further research with larger patient cohorts is recommended to comprehensively assess the association between LOH in FANCF and patient survival. PMID: 28440438
- This study reports three patients who illustrate the clinical variability within the FA-F group. Analysis suggests a potentially more severe phenotype for individuals with the common c.484_485delCT mutation. PMID: 27714961
- Methylation of the FANCF gene promoter region CpG island is strongly associated with the susceptibility and clinicopathologic features of epithelial ovarian cancer. PMID: 26507869
- A detailed examination of three electively aborted fetuses from one family and one affected girl from another family indicated an association of FANCF loss-of-function mutations with a severe phenotype characterized by multiple malformations. PMID: 26033879
- Data suggests that the Fanconi anemia group F protein/BRCA1/2 proteins pathway may be a promising target for reversing adriamycin (ADR) resistance in leukemia treatment. PMID: 24996439
- Silencing of FANCF enhanced the antiproliferative effect of ADM in OVCAR3 cells. PMID: 23440494
- FANCF methylation is a rare occurrence in Japanese primary invasive breast cancer. PMID: 19813073
- Data identifies the gene encoding Fanconi F (FANCF) as an ICSBP target gene. PMID: 19801548
- Inactivation of the FANC-BRCA pathway is relatively common in solid tumors and may be related to tobacco and alcohol exposure and survival. PMID: 14647419
- Inactivation of genes in the FA-BRCA pathway through epigenetic alterations has been found in a significant proportion of cervix cancer patients, suggesting a major role for this pathway in the development of cervical cancer. PMID: 15126331
- FANCF functions as a flexible adaptor protein that plays a crucial role in the proper assembly of the FA core complex. PMID: 15262960
- Results showed that FANCF methylation regulates the expression of FANCF at both mRNA and protein levels. Methylation-induced inactivation of FANCF plays a significant role in the development of ovarian cancers by disrupting the FA-BRCA pathway. PMID: 16418574
- The human FANCF protein possesses specific structural components that function in the assembly of a DNA damage signaling complex. PMID: 17082180
- FANCF methylation was infrequent in breast tumors. PMID: 17932744
- This study does not support methylation-dependent silencing of FANCF as a mechanism for sensitization to platinum-based chemotherapy in ovarian cancer. PMID: 18414472
